GlassScriptPhysician profile
Tana K Cooper
NPI 1174730519
$25,277.41
in general payments reported to CMS, 2019-2025
26 companies · $10K in 2025
The $10K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42.93 · 2020: $182 · 2021: $333 · 2022: $247 · 2023: $3,831 · 2024: $11K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $2,532 · Honoraria: $2,375 · Travel and Lodging: $265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,300.00 |
| Food and Beverage | $2,532.01 |
| Honoraria | $2,375.00 |
| Travel and Lodging | $265.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $20,434.60 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Myriad Women'S Health, INC. | $2,375.00 | 2023 | Myrisk |
| Renalytix Ai, INC. | $543.17 | 2023-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Lilly USA, LLC | $346.31 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $269.82 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $241.78 | 2023-2025 | Repatha, Evenity, Prolia |
| Averitas Pharma INC. | $198.69 | 2023-2025 | Qutenza |
| Bayer Healthcare Pharmaceuticals INC. | $120.21 | 2024-2025 | |
| Silk Road Medical, INC. | $120.02 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Novo Nordisk INC | $101.03 | 2020-2023 | Wegovy |
| Grt US Holding, INC. | $87.16 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $75.70 | 2021 | |
| Merck Sharp & Dohme LLC | $65.49 | 2020-2021 | |
| Pfizer INC. | $37.60 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.86 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $34.82 | 2022 | |
| Exact Sciences Corporation | $30.98 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $30.16 | 2022 | |
| Genentech USA, INC. | $27.77 | 2021 | |
| Medtronic, INC. | $18.01 | 2025 | Inceptiv |
| Kowa Pharmaceuticals America, INC. | $14.75 | 2021 | |
| Cardiovascular Systems INC. | $14.60 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.28 | 2025 | Jardiance |
| Idorsia Pharmaceuticals US INC | $13.81 | 2023 | Quviviq |
| Tactile Systems Technology INC | $12.93 | 2021 | |
| Astellas Pharma US INC | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tana Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.